Total Funding
56
49
Total FundingSeries H raised
Growth Score
-8 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
29446
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
- Ian Nicholson: Chief Executive OfficerPast Role: Celltech Therapeutics, Senior Vice President, Business Development
- Tony Kennedy: Chief Scientific and Development OfficerPast Role: Vantia Therapeutics, Led the Development Functions (UK)
About the Company
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into
chemistry-driven discovery. They have also assembled an experienced development capacity.
